Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs like Zepbound and Wegovy in exchange for tariff relief and wider Medicare access.

President Trump appeared in the oval office with executives from the companies behind GLP1 weight loss drug Wegovy and Zepbound to announce new costs for Medicare recipients and price reductions set t...

Under this new deal, the monthly cost for Wegovy will drop over $1,000 to $250 per month, while Zepbound’s monthly cost will dip to $346.